Jie Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7647509/publications.pdf

Version: 2024-02-01

		331670	175258
57	3,237 citations	21	52
papers	citations	h-index	g-index
58	58	58	3869
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2019, 4, 389-398.	8.1	616
2	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 739-752.	8.1	481
3	Epidemiology of COVIDâ€19: A systematic review and metaâ€analysis of clinical characteristics, risk factors, and outcomes. Journal of Medical Virology, 2021, 93, 1449-1458.	5.0	450
4	2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 2809-2817.e28.	4.4	255
5	Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. Journal of Clinical and Translational Hepatology, 2020, 8, 1-5.	1.4	239
6	An Algorithm for Risk Assessment and Intervention of Mother to Child Transmission of Hepatitis B Virus. Clinical Gastroenterology and Hepatology, 2012, 10, 452-459.	4.4	224
7	Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 750-757.	2.8	80
8	The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. Journal of Hepatology, 2021, 75, 454-461.	3.7	70
9	Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. Virology Journal, 2011, 8, 113.	3.4	68
10	The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatology International, 2020, 14, 259-269.	4.2	56
11	Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Journal of Infectious Diseases, 2021, 224, 294-302.	4.0	51
12	Generative adversarial networks in medical image segmentation: A review. Computers in Biology and Medicine, 2022, 140, 105063.	7.0	41
13	Genes related to the very early stage of ConA-induced fulminant hepatitis: a gene-chip-based study in a mouse model. BMC Genomics, 2010, 11, 240.	2.8	40
14	HBcAg induces interleukinâ€10 production, inhibiting HBcAgâ€specific Th17 responses in chronic hepatitis B patients. Immunology and Cell Biology, 2010, 88, 834-841.	2.3	38
15	Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. Antiviral Research, 2010, 85, 463-469.	4.1	35
16	Long non-coding RNAs LOC285194, RP11-462C24.1 and Nbla12061 in serum provide a new approach for distinguishing patients with colorectal cancer from healthy controls. Oncotarget, 2016, 7, 70769-70778.	1.8	34
17	Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (â‰ち cm) after initial curative resection. European Radiology, 2020, 30, 6357-6368.	4.5	32
18	NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea. Digestive Diseases, 2021, 39, 634-645.	1.9	29

#	Article	IF	CITATIONS
19	Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. Journal of Viral Hepatitis, 2021, 28, 1025-1033.	2.0	29
20	Hepatitis B e-antigen Persistency is Associated with the Properties of HBV-Specific CD8 T Cells in CHB Patients. Journal of Clinical Immunology, 2011, 31, 195-204.	3.8	28
21	Metaâ€analysis: global prevalence, trend and forecasting of nonâ€alcoholic fatty liver disease in children and adolescents, 2000–2021. Alimentary Pharmacology and Therapeutics, 2022, 56, 396-406.	3.7	28
22	Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus. Hepatology Research, 2016, 46, E181-8.	3.4	27
23	ALT Levels for Asians With Metabolic Diseases: A Metaâ€analysis of 86 Studies With Individual Patient Data Validation. Hepatology Communications, 2020, 4, 1624-1636.	4.3	21
24	APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems. Virus Research, 2010, 151, 213-219.	2,2	20
25	Regulatory Role of CD4+CD25+Foxp3+ Regulatory T Cells on IL-17-Secreting T Cells in Chronic Hepatitis B Patients. Digestive Diseases and Sciences, 2014, 59, 1475-1483.	2.3	20
26	Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 635-643.	1.5	20
27	Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver International, 2020, 40, 1052-1061.	3.9	20
28	Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. International Journal of Hyperthermia, 2021, 38, 875-886.	2.5	17
29	Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis. Hpb, 2021, 23, 512-519.	0.3	17
30	The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. American Journal of Gastroenterology, 2021, 116, 2068-2078.	0.4	16
31	Management of COVID-19 patients with chronic liver diseases and liver transplants. Annals of Hepatology, 2022, 27, 100653.	1.5	13
32	Management of Chronic Hepatitis B in Pregnancy. Journal of Clinical Gastroenterology, 2017, 51, 789-795.	2.2	11
33	A microarray analysis of early activated pathways in concanavalin A-induced hepatitis. Journal of Zhejiang University: Science B, 2010, 11, 366-377.	2.8	10
34	Interleukin-21 Responses in Patients with Chronic Hepatitis B. Journal of Interferon and Cytokine Research, 2015, 35, 134-142.	1.2	10
35	Overexpression of the metastasisâ€essociated gene <i>MTA3</i> correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1525-1529.	2.8	10
36	Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis. Digestive Diseases, 2022, 40, 734-744.	1.9	10

#	Article	IF	CITATIONS
37	Microwave ablation shows similar survival outcomes compared with surgical resection for hepatocellular carcinoma between 3 and 5 cm. International Journal of Hyperthermia, 2020, 37, 1345-1353.	2.5	9
38	Associations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review). Molecular Medicine Reports, 2015, 12, 6405-6414.	2.4	7
39	The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: a prospective, multicenter, large-sample cohort study. BMC Medicine, 2021, 19, 148.	5.5	7
40	High hepatitis C virus cure rates with approved interferonâ€free directâ€acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 767-774.	2.8	6
41	The role of interleukinâ€27 in predicting spontaneous <scp>HB</scp> eAg seroconversion in chronic hepatitis B infection. Liver International, 2017, 37, 1287-1294.	3.9	5
42	Diagnosis of Pre-HCC Disease by Hepatobiliary-Specific Contrast-Enhanced Magnetic Resonance Imaging: A Review. Digestive Diseases and Sciences, 2020, 65, 2492-2502.	2.3	5
43	A K-nearest Neighbor Model to Predict Early Recurrence of Hepatocellular Carcinoma After Resection. Journal of Clinical and Translational Hepatology, 2022, 10, 600-607.	1.4	5
44	Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis. International Journal of Hyperthermia, 2022, 39, 455-465.	2.5	5
45	The latent period of coronavirus disease 2019 with SARSâ€CoVâ€2 B.1.617.2 Delta variant of concern in the postvaccination era. Immunity, Inflammation and Disease, 2022, 10, .	2.7	5
46	Derivation and validation of prognostic models for predicting survival outcomes in Acuteâ€onâ€chronic liver failure patients. Journal of Viral Hepatitis, 2021, 28, 1719-1728.	2.0	4
47	Nonâ€invasive diagnosis methods are needed in paediatric nonâ€alcoholic fatty liver disease. Liver International, 2021, 41, 1161-1161.	3.9	3
48	A New Concept: Preâ€HCC Disease. Hepatology, 2018, 68, 1662-1662.	7.3	2
49	Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment. Journal of Hepatology, 2019, 70, 209-211.	3.7	2
50	Comment on Cai et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care 2020;43:1392–1398. Diabetes Care, 2020, 43, e160-e161.	8.6	2
51	Letter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B?. Hepatology, 2022, 75, 233-234.	7.3	2
52	Nonâ€alcoholic fatty liver disease (NAFLD) in Asiaâ€"More efforts are needed. Liver International, 2020, 40, 3144-3144.	3.9	1
53	Chronic hepatitis B and fatty liver –weal or woe?. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.4	1
54	Letter to the Editor: Chronic Hepatitis B and Nonalcoholic Steatohepatitis: Is "Fat―All Bad?. Hepatology, 2020, 71, 768-768.	7.3	0

#	Article	IF	CITATIONS
55	A prediction model of major complications after radiofrequency ablation for recurrent hepatocellular carcinoma patients. European Journal of Radiology, 2021, 140, 109635.	2.6	0
56	Nonalcoholic Fatty Liver Disease in Children: where are we?. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
57	Establishment and Evaluation of a Prediction Model of BLR for Severity in Coronavirus Disease 2019. Infectious Diseases & Immunity, 2022, 2, 100-108.	0.6	0